HLB KRX:028300KOSDAQ
HLB · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days4
DART filings, 7 days0
Articles tracked4since Sep 11
In Q2 2026, HLB reported revenue of ₩28.0bn, up 78.0% year on year, and an operating loss of ₩22.5bn. HLB (HLB) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 12 with 2 articles.
HLB quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩28.0bn | +78.0% | −₩22.5bn | −₩80.4bn |
| Q1 2026 | ₩18.7bn | +5.8% | −₩23.2bn | −₩40.9bn |
| Q4 2025 derived | ₩28.7bn | +13.6% | −₩29.4bn | −₩29.3bn |
| Q3 2025 | ₩22.1bn | +30.4% | −₩23.0bn | −₩76.4bn |
| Q2 2025 | ₩15.7bn | +6.3% | −₩23.1bn | −₩60.8bn |
| Q1 2025 | ₩17.7bn | +58.4% | −₩28.8bn | −₩68.9bn |
| Q4 2024 derived | ₩25.2bn | +179.6% | −₩25.7bn | −₩29.7bn |
| Q3 2024 | ₩17.0bn | +74.2% | −₩19.6bn | ₩590m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
HLB top stories 2 weeks, by number of outlets
- 1
- 2
- 3
Latest HLB news Korean headlines
-
DRTECH Surges on Return to Market; HLB Innovation, L&K Biomed Rise[K-bio pulse]
1 more on this story · 1 outlets